Recurrent thrombocytopenia with hemolytic anemia in a boy aged 3 years
ZENG Min-Hui1, HE Xiang-Ling1, TIAN Xin1, HUANG Yu-Hui2
Department of Pediatric Hematologic Oncology, Hunan Provincial People's Hospital/Children's Medical Center of First Affiliated Hospital of Hunan Normal University, Changsha 410005, China
Abstract A boy, aged 3 years and 8 months, had recurrent thrombocytopenia with hemolytic anemia for more than 3 years. The physical examination showed no enlargement of the liver, spleen, and lymph nodes or finger deformities. Laboratory results showed a negative result of the direct antiglobulin test, normal coagulation function, and increases in bilirubin, lactate dehydrogenase and reticulocytes. The results of von Willebrand factor-cleaving protease ADAMTS13 activity assay showed extreme deficiency, and antibody assay showed negative ADAMTS13 inhibitory autoantibodies. Next-generation sequence showed compound heterozygous mutation in the ADAMTS13 gene. The boy was diagnosed with congenital thrombotic thrombocytopenic purpura. This disease may be easily misdiagnosed as Evans syndrome and is difficult to diagnose in clinical practice. The child had developed the disease since birth, but it took 3 years to make a confirmed diagnosis. Therefore, congenital thrombotic thrombocytopenic purpura should be considered for children with jaundice at birth, recurrent thrombocytopenia with hemolytic anemia, and negative results of the direct antiglobulin test. The detection of ADAMTS13 activity and ADAMTS13 inhibitory autoantibodies should be performed as soon as possible for a definite diagnosis, and gene detection should be performed to make a confirmed diagnosis when necessary.
Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocyto-penic purpura):a cross-sectional analysis of the French national registry for thrombotic microangiopathy[J]. Lancet Haematol, 2016, 3(5):e237-e245.
[3]
Joly BS, Stepanian A, Leblanc T, et al. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency:a cohort study of the French national registry for thrombotic microangiopathy[J]. Lancet Haematol, 2016, 3(11):e537-e546.
[4]
Carmi O, Berla M, Shoenfeld Y, et al. Diagnosis and management of catastrophic antiphospholipid syndrome[J]. Expert Rev Hematol, 2017, 10(4):365-374.
Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen)[J]. Genet Med, 2020, 22(2):245-257.
[12]
Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2020, 18(10):2486-2495.
[13]
Moschcowitz E. Hyaline thrombosis of terminal arterioles and capillaries:a hitherto undescribed disease[J]. Proc NY Pathol Soc, 1924, 24:4-21.
[14]
Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura[J]. Blood, 2012, 120(2):440-448.
[15]
Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura[J]. Nature, 2001, 413(6855):488-494.
[16]
Scully M. Hereditary thrombotic thrombocytopenic purpura[J]. Haematologica, 2019, 104(10):1916-1918.
[17]
van Dorland HA, Taleghani MM, Sakai K, et al. The international hereditary thrombotic thrombocytopenic purpura registry:key findings at enrollment until 2017[J]. Haematologica, 2019, 104(10):2107-2115.
[18]
Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome[J]. Blood, 2004, 103(4):1305-1310.
Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura[J]. N Engl J Med, 2019, 380(4):335-346.
[21]
Saha M, McDaniel JK, Zheng XL. Thrombotic thrombocy-topenic purpura:pathogenesis, diagnosis and potential novel therapeutics[J]. J Thromb Haemost, 2017, 15(10):1889-1900.
[22]
Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2020, 18(10):2496-2502.
[23]
Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura:toward targeted therapy and precision medicine[J]. Res Pract Thromb Haemost, 2019, 3(1):26-37.
[24]
Adili R, Holinstat M. Formation and resolution of pial microvascular thrombosis in a mouse model of thrombotic thrombocytopenic purpura[J]. Arterioscler Thromb Vasc Biol, 2019, 39(9):1817-1830.
[25]
Kopić A, Benamara K, Piskernik C, et al. Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2016, 14(7):1410-1419.
[26]
Scully M, Knöbl P, Kentouche K, et al. Recombinant ADAMTS-13:first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura[J]. Blood, 2017, 130(19):2055-2063.
